Mukaltin tablets 50 mg No. 30

Instructions for Mukaltin tablets 50 mg No. 30

Composition

active ingredient: 1 tablet contains mucaltin 50 mg;

Excipients: lactose monohydrate, croscarmellose sodium, heavy magnesium carbonate, aspartame, talc, calcium stearate.

Dosage form

Pills.

Main physicochemical properties: tablets of grayish-brownish color with inclusions, flat-cylindrical, with a score and a bevel.

Pharmacotherapeutic group

Expectorants. ATX code R05C A05.

Pharmacological properties

Mukaltin® is an effective expectorant, the action of which is due to secretolytic and bronchodilator properties. The drug has a moderate antitussive effect, reduces the number of coughing attacks and their intensity. It has softening, anti-inflammatory and enveloping properties. Normalizes altered bronchopulmonary secretion, improves sputum discharge: reduces its viscosity and adhesive properties, facilitates the movement of sputum from the lower to the upper respiratory tract and its expectoration.

Indication

Cough in acute and chronic respiratory diseases accompanied by the formation of thick and viscous bronchial secretions and/or impaired expectoration: bronchitis, pneumonia, bronchiectasis, bronchial asthma.

Contraindication

Hypersensitivity to mucaltin or to other components of the drug.

Interaction with other medicinal products and other types of interactions

There are currently no data on drug interactions with Mukaltin®. Do not prescribe simultaneously with drugs that suppress cough (codeine).

Application features

Sometimes in patients with chronic inflammatory lung diseases at the beginning of treatment with Mukaltin®, sputum viscosity may increase due to the separation of sputum that has accumulated in the bronchial tree and contains a large amount of detritus, proteins and inflammatory elements. Therefore, in case of diffuse bronchial lesions, significant changes in the physicochemical properties of sputum and a decrease in mucociliary transport, Mukaltin® therapy should be combined with the appointment of mucolytic drugs (bromhexine and others).

It is advisable to take single doses of the drug every 4 hours.

Ability to influence reaction speed when driving vehicles or other mechanisms

The drug does not affect driving or operating other dangerous machinery.

Use during pregnancy or breastfeeding

There is no experience with the use of the drug during pregnancy or breastfeeding.

Method of administration and doses

Do not chew the tablets, drink plenty of water.

Adults and children over 12 years of age should be prescribed 2 tablets 4 times a day before meals. Doses for children, depending on age, are: 1-3 years - 1 tablet 3 times a day, 3-12 years - 1 tablet 4 times a day.

When used in children, the drug can be dissolved in ⅓ cup of warm water, adding sugar or fruit syrup if desired.

The course of treatment is from 7 days to 1-2 months, depending on the form of the disease.

Children

The drug should be used in children over 1 year of age.

Overdose

When using the indicated therapeutic doses of the drug, overdose is impossible. With prolonged use or exceeding the indicated doses, nausea and vomiting may occur.

Therapy is symptomatic.

Adverse reactions

In some cases, allergic reactions may occur, including rash, hives, and itching of the skin.

Expiration date

4 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

30 tablets in a jar, 1 jar (container) in a pack.

Vacation category

Without a prescription.

Producer

PJSC "Galychpharm".

Location of the manufacturer and its business address

Ukraine, 79024, Lviv, Opryshkivska St., 6/8.